If the Supreme Court rules this summer that federal-run Obamacare exchanges can't provide health insurance subsidies, the results could be chaotic for those receiving the financial aid across the country-but especially in the South.
If the Supreme Court rules this summer that federal-run Obamacare exchanges can't provide health insurance subsidies, the results could be chaotic for those receiving the financial aid across the country—but especially in the South.
About 11.7 million people have signed up for 2015 exchange plans, including 8.8 million who selected coverage in states with federal-run exchanges, the Obama administration announced Tuesday. The vast majority of those people are receiving subsidies, which on average cuts monthly premiums by 72%. Those size of the typical discount, though, varies by state.
Read more at Kaiser Health News: http://wapo.st/1L3dXqM
Examining Telehealth Uptake to Increase Equitable Care Access
January 26th 2023To mark the publication of The American Journal of Managed Care®’s 12th annual health IT issue, on this episode of Managed Care Cast, we speak with Christopher M. Whaley, PhD, health care economist at the RAND Corporation, who focuses on health economics issues, including the influence of the COVID-19 pandemic on health care delivery.
Listen
High-Deductible Health Plans and Their Potential Impact on the US Drug Epidemic
October 13th 2022On this episode of Managed Care Cast, we speak with Matthew D. Eisenberg, PhD, lead author of a study published in the October issue of The American Journal of Managed Care® that investigated the use of high-deductible health plans and their impact on substance use disorder care and spending.
Listen
FDA Approves Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
January 28th 2023The FDA has approved pirtobrutinib (Jaypirca) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma following at least 2 lines of systemic therapy, including a previous Bruton tyrosine kinase (BTK) inhibitor.
Read More
FDA Approves Elacestrant for ER+/HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer
January 27th 2023The FDA has approved elacestrant (Orserdu) for the treatment of postmenopausal women or adult men with estrogen receptor–positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least 1 line of endocrine therapy.
Read More
2 Clarke Drive
Cranbury, NJ 08512